1. Home
  2. ALMS
  3. ALMS News

Latest ALUMIS INC (ALMS) News on April 2, 2025

Alumis and Kaken sign agreement in Japan to develop ESK-001
ALMS

Pharmaceutical Technology

8 days ago

Alumis and Kaken sign agreement in Japan to develop ESK-001

ALMS

MT Newswires

8 days ago

Sector Update: Health Care Stocks Steady Premarket Tuesday

ALMS

MT Newswires

8 days ago

Alumis, Kaken Pharmaceutical Enter Collaboration, Licensing Deal for Dermatology Drug

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
ALMS

GlobeNewswire

8 days ago

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Why Alumis Inc. (ALMS) Went Down On Thursday?
ALMS

Insider Monkey

12 days ago

Why Alumis Inc. (ALMS) Went Down On Thursday?

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
ALMS

GlobeNewswire

14 days ago

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis to Present at Leerink's 2025 Global Healthcare Conference
ALMS

GlobeNewswire

23 days ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
ALMS

GlobeNewswire

25 days ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

ALMS

MT Newswires

a month ago

Acelyrin Reaffirms Merger Deal With Alumis

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
ALMS

GlobeNewswire

a month ago

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
ALMS

GlobeNewswire

a month ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
ALMS

GlobeNewswire

a month ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
ALMS

GlobeNewswire

a month ago

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
ALMS

GlobeNewswire

a month ago

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
ALMS

GlobeNewswire

a month ago

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
ALMS

GlobeNewswire

2 months ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

ALMS

MT Newswires

2 months ago

Oppenheimer Adjusts Price Target on Alumis to $26 From $32, Keeps Outperform Rating

Alumis and Acelyrin sign merger agreement
ALMS

Pharmaceutical Technology

2 months ago

Alumis and Acelyrin sign merger agreement

We're Keeping An Eye On Alumis' (NASDAQ:ALMS) Cash Burn Rate
ALMS

Simply Wall St.

2 months ago

We're Keeping An Eye On Alumis' (NASDAQ:ALMS) Cash Burn Rate

Immune drugmakers Alumis and Acelyrin to merge
ALMS

BioPharma Dive

2 months ago

Immune drugmakers Alumis and Acelyrin to merge

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
ALMS

GlobeNewswire

2 months ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Strengthens Leadership Team with Key Appointments
ALMS

GlobeNewswire

2 months ago

Alumis Strengthens Leadership Team with Key Appointments

Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS),
ALMS

Simply Wall St.

3 months ago

Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS),

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
ALMS

GlobeNewswire

3 months ago

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
ALMS

GlobeNewswire

5 months ago

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
ALMS

GlobeNewswire

5 months ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
ALMS

GlobeNewswire

5 months ago

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
ALMS

GlobeNewswire

6 months ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis to Participate in Upcoming September Investor Conferences
ALMS

GlobeNewswire

7 months ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
ALMS

GlobeNewswire

8 months ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
ALMS

GlobeNewswire

8 months ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Share on Social Networks: